Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.65 |
| ▸ | WIZ | O95785 | 1/20 | 0.56 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828023 | 0.91 | CRBN (0.69) | CRBN | |
| SCHEMBL24319331 | 0.87 | CRBN (0.69) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL17552859 | 0.87 | CRBN (0.69) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25428752 | 0.85 | CRBN (0.60) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL25996067 | 0.85 | CRBN (0.69) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL22566723 | 0.84 | IKZF2 (0.65) | CRBNWIZIKZF2 | |
| SCHEMBL19503638 | 0.84 | CRBN (0.65) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL34465960 | 0.84 | CRBN (0.65) | CRBNWIZIKZF2CSNK1A1 | |
| SCHEMBL30851278 | 0.84 | CRBN (0.69) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL34466761 | 0.84 | CRBN (0.65) | CRBNWIZIKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-03-09 | — | — | US | disclosed |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885WIZ 3934/4885IKZF2 2170/4885 |
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | CRBN 421/4885WIZ 1458/4885IKZF2 409/4885 |
| US-20200399266-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | CRBN 527/4885WIZ 3588/4885IKZF2 3331/4885 |
| US-20230070613-A1 | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | PTK6, NEK6, GRK6 | CRBN 871/4885WIZ 3122/4885IKZF2 3589/4885 |
| US-20230167106-A1 | SERINE THREONINE KINASE (AKT) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE | MKNK1, MKNK2, MTOR | CRBN 527/4885WIZ 3588/4885IKZF2 3331/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | CRBN 3528/4885WIZ 2314/4885IKZF2 3455/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | CRBN 194/4885WIZ 3623/4885IKZF2 1536/4885 |
| US-11472799-B2 | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use | MKNK1, MKNK2, MTOR | CRBN 527/4885WIZ 3588/4885IKZF2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.